AbbVie stock gains as RINVOQ wins European approval

Published on 09/22/2026 at 12:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AbbVie stock opened at USD 265.06 on September 22, 2026, near its 52-week high. Q2 revenue rose 10.2 percent to USD 16.99 billion.

Fotorealistisches Pharma-Forschungslabor mit Petrischalen und Wissenschaftlern in Schutzkleidung — AbbVie Inc. US00287Y1091 fotorealistisches Pharma Forschungslabor mit Petrischalen Wissenschaftlern Immunologie Onkologie Biopharma, Illustration mit AI erstellt.

AbbVie Inc. (ISIN US00287Y1091) opened at USD 265.06 on the NYSE on September 22, 2026, only USD 2.41 below its 52-week high of USD 267.47. The company also received a European Commission approval for RINVOQ on September 22, 2026, extending the drug's use to children with active polyarticular juvenile idiopathic arthritis, according to MarketBeat.

RINVOQ adds a pediatric indication

The regulatory decision gives AbbVie another approved use for RINVOQ, one of its key growth products. The September 22, 2026 approval covers children with active polyarticular juvenile idiopathic arthritis, providing a new pediatric treatment setting for the drug, as reported by StockTitan.

The market backdrop is important because AbbVie entered the latest reporting period with double-digit top-line growth. In the quarter ended June 30, 2026, revenue reached USD 16.99 billion, up 10.16 percent from USD 15.42 billion a year earlier, according to Finanzen.

Second quarter delivered a measurable beat

AbbVie reported USD 3.65 in EPS for the quarter ended June 30, 2026, compared with USD 2.97 in the prior-year period. The result exceeded the USD 3.61 consensus estimate by USD 0.04, while quarterly revenue topped the USD 16.80 billion estimate by USD 0.19 billion, according to MarketBeat.

That comparison gives the RINVOQ decision a broader earnings context. The latest quarter combined 10.2 percent year-over-year revenue growth with an EPS beat of USD 0.04, although coverage also described the full-year EPS outlook as a slight miss against expectations, according to StockStory.

Stock remains close to its yearly high

AbbVie had a market capitalization of USD 468.31 billion on September 22, 2026. Its 52-week range was USD 190.75 to USD 267.47, placing the opening price at roughly 39 percent above the low and less than 1 percent below the high, based on MarketBeat data.

The valuation leaves less room for an earnings disappointment to be ignored. MarketBeat data showed an average rating of Moderate Buy and an average price target of USD 276.64 on September 22, 2026, which was USD 11.58 above the opening price.

AbbVie stock holds near the high

AbbVie stock opened at USD 265.06 on the NYSE on September 22, 2026. The reference price is therefore close to the 52-week high of USD 267.47, while the June 30, 2026 quarter supplies the latest reported comparison with USD 16.99 billion in revenue and USD 3.65 EPS.